J&J Antipsychotic Paliperidone ER Moves Into Phase III
Executive Summary
Johnson & Johnson has moved a potential successor compound to the antipsychotic Risperdal into Phase III clinical studies
You may also be interested in...
Invega Approval Gives J&J A Year To Move Risperdal Patients To Paliperidone
J&J has slightly over one year to switch patients to Invega before its blockbuster atypical antipsychotic Risperdal loses patent protection
Invega Approval Gives J&J A Year To Move Risperdal Patients To Paliperidone
J&J has slightly over one year to switch patients to Invega before its blockbuster atypical antipsychotic Risperdal loses patent protection
J&J submits Risperdal follow-on
Johnson & Johnson submits NDA for paliperidone extended-release Nov. 29, giving the schizophrenia therapy a user fee date in late September 2006. The timeline puts J&J on track to launch paliperidone ER in advance of generic competition to Risperdal (risperidone), which could lose exclusivity as early as mid-2008. The agent is a metabolite of risperidone and uses J&J's proprietary OROS controlled-release technology, gained through the company's acquisition of Alza in 1999 (1"The Pink Sheet" April 19, 2004, p. 12)...